Research Press Releases

Latest Releases

Title	Date
Vernalis licenses V2006 to RedoxTherapies Inc for use in immuno-oncology	09 October 2014
Interim results for the six months ended 30 June 2014	05 August 2014
Vernalis and Servier achieve two Research Milestones in their Oncology Collaborations	04 August 2014
Vernalis and Servier achieve Research Milestone as BCL-2 inhibitor drug candidate enters Phase I	19 June 2014
Promising Results of Phase Ib/II Proof-of-Concept Study in Attention Deficit Hyperactivity Disorder (ADHD) with V81444	24 April 2014
Vernalis Research wins Queen’s Award for Enterprise	22 April 2014
Announcement of Results for the year ended 31 December 2013	01 April 2014
Vernalis and Asahi Kasei Pharma Achieve Research Milestone	27 March 2014
Notice of Results for the Twelve Months Ended 31 December 2013	05 March 2014

Page 4 of 4

Start
Prev
1
2
3
4
Next
End

Latest News

Year-End Trading Update and Notice of Full Year Results

Continued steady growth of Tuzistra^® XR annualised prescription run rate through drug's second cough cold season; similar growth rate expected for 2017/18 season

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Explore the pipeline ...

NCE Pipeline

Explore the pipeline ...

Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet